ClinicalTrials.gg
RecruitingNCT07344311Updated Oct 16, 2026

A Phase I Trial of A-CAR032 in Participants With mCRPC

A Phase 1 interventional study of dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection in Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer, sponsored by Shanghai AbelZeta Ltd.. Recruiting at 4 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Shanghai AbelZeta Ltd. (part of AbelZeta Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 15, 2026Site recruiting status changed1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 541 studies in Prostatic Neoplasms with a site in China — 280 open to participants now, 342 under way, 51 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
362nd of 435
27 · median 100
Started
2026
with 81 others
Phase 1
97 of 541
54 open now
Primary completion
2027-01
later than 170 of 341 live
Registered
459th of 541
by date

Among the 541 studies in Prostatic Neoplasms with a site in China, this one is the 362nd largest by planned enrollment of the 435 interventional ones that give a count, is one of 82 that started in 2026, is one of 97 in phase 1, reaches primary completion later than 170 of the 341 other live ones, and was the 459th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

280 of the 541 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

275 more — sign in →

All 280 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 541 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This FTiH, single-arm, open-label, investigator-initiated Phase I trial will evaluate the safety, antitumour activity, CK/pharmacodynamics (PD), biomarkers, immunogenicity, and feasibility of A-CAR032 in adult participants with mCRPC, who have previously progressed after ARPI treatment of prostate cancer (whether before or in the metastatic castration-resistant setting) and, in the judgment of the investigator, are ineligible for standard treatment.

Read the detailed description

The study consists of two parts: Part 1-Dose Escalation and Part 2-Dose Expansion. Participants in the study will proceed through screening, apheresis, bridging therapy (if appropriate), lymphodepletion, CAR-T cell infusion, and subsequent follow-up (including Stage 1, 2 and 3).

03

Conditions studied

  • Prostate Cancer
  • Metastatic Castration-Resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be 18 years or older at the time of signing the ICF. Type of Participant and Disease Characteristics
  2. Participants with:

    1. A confirmed diagnosis of adenocarcinoma of the prostate without known neuroendocrine differentiation or small cell features.
    2. Castration-resistant prostate cancer as defined by disease progression despite castration by orchiectomy or ongoing luteinising hormone-releasing hormone analogue. Participants receiving medical castration therapy with gonadotropin-releasing hormone analogues should continue this treatment during the study.
    3. Measurable PSA≥1 ng/mL AND
    4. Evidence of progression within 6 months prior to screening
  3. Participant has previously received an ARPI (ie, abiraterone, enzalutamide, apalutamide, darolutamide, rezvilutamide) whether before or in the metastatic castration-resistant setting, and in the judgment of the investigator, be ineligible for standard treatment.
  4. Minimum of > 12 weeks prior to apheresis in the opinion of the investigator.
  5. Adequate organ and marrow function
  6. Consent and provision of tumour material to assess STEAP2 expression and other correlative biomarkers retrospectively with pre- and post-treatment .
  7. use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  8. The participant voluntarily participates in the study, and the individual or their legal guardian signs the ICF.

Exclusion criteria

Exclusion Criteria:

  1. Known life-threatening allergies, , or intolerance to the CAR-T product or its , including dimethyl sulfoxide (DMSO).
  2. to lymphodepleting agents, including fludarabine and/or cyclophosphamide.
  3. History of another primary except for:

    1. Malignancy treated with curative intent and with no known active disease within 3 years before the apheresis and of low potential risk for recurrence.
    2. Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease.
    3. Adequately treated carcinoma in situ without evidence of disease.
  4. Participants with known .
  5. History of splenectomy or organ transplantation.
  6. Prior treatment with:

    1. Any CAR-T therapy. OR
    2. Any therapy that is targeting STEAP2.
  7. Active or prior documented or inflammatory disorders
  8. Cardiac arrhythmias which are symptomatic or require treatment unless controlled by pacemaker (judged by investigator); symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
  9. Active infection, including:

    1. infection is defined as hepatitis B surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcAb) positive and HBV DNA detectable.
    2. infection is defined as HCV antibody positive and HCV RNA positive.
    3. CMV infection is defined as CMV DNA detectable.
    4. Syphilis infection is defined as syphilis antigen and antibody positive.
    5. infection is defined as HIV 1/2 antibody positive.
    6. Other persistent or active infections requiring systemic treatment (prophylactic use of anti-infective drugs is allowed).
  10. Patients with central nervous system (CNS) diseases:
  11. Obvious risk or tendency of bleeding or active bleeding (eg, hemoptysis, tumour bleeding, history of von Willebrand disease or hemophilia etc.).
  12. Plans to father a child during the study period.
  13. Patients with alcohol or drug abuse.
  14. Participants may not receive full-dose long acting oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose from the time of to 28 days post infusion of A-CAR032. Use of short acting direct oral anticoagulants for therapeutic and prophylactic purposes are permitted.
  15. Received the following:

    1. Major surgery within 4 weeks prior to apheresis or existence of unhealed wound, or planned major surgery within 4 weeks of the study treatment administration
    2. (except inhaled steroids) or other immunomodulators (including interleukins, interferons, and thymosins) of systemic therapeutic dose, and systemic corticosteroids at doses exceeding 10 mg/day of prednisone or equivalent within 5 half-lives or 7 days (whichever is shorter) prior to apheresis.
  16. Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy targeted therapy, biologic therapy, tumour embolisation, or monoclonal antibodies, product) within 5 half-lives or ≤ 21 days (whichever is shorter) prior to apheresis.
  17. Radiotherapy within 4 weeks of apheresis (However, if the radiation portal covered ≤ 5% of the bone marrow reserve, the participant is eligible irrespective of the end date of radiotherapy); or within 6 months or 5 half-lives (whichever is longer) if local radioactive particle implantation was performed.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    A-CAR032

    Part 1 will follow an i3+3 design which is employed to explore the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE). Three dose levels of A-CAR032are initially planned with a minimum of 3 and maximum of 9 participants per dose level. The safety review committee (SRC) may suggest exploration of intermediate dose levels or additional higher or lower dose levels based on the available data, but will not exceed 3 times the current dose or 3 times the highest dose that has been determined safe by the SRC.Part 2 at the RDE of A-CAR032 will be initiated, if data support, to further evaluate the safety, CK, efficacy and potential biological activity of study intervention. Approximately 12 evaluable participants will be enrolled in Part 2.

    Biological: dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection

Interventions

  • BiologicaldnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection

    dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection.single infusion intravenously.

06

What researchers measure

Primary outcomes

  1. Dose Escalation (Part 1):Safety

    Incidence of AEs/SAEs

    Time frame: From ICF signature until 15 years post A-CAR032 infusion

  2. Dose Escalation (Part 1):Safety

    Occurrence of DLTs/DLT-like events

    Time frame: Throughout the 28 days post A-CAR032 infusion

  3. Dose Escalation (Part 1):Safety

    Changes from baseline in laboratory parameters, vital signs, and ECGs

    Time frame: From ICF signature until 12 months post A-CAR032 infusion

  4. Dose Expansion (Part 2):Safety

    Incidence of AEs/SAEs

    Time frame: From ICF signature until 15 years post A-CAR032 infusion

  5. Dose Expansion (Part 2):Safety

    Incidence of DLT-like events

    Time frame: Throughout the 28 days post A-CAR032 infusion

  6. Dose Expansion (Part 2):Safety

    Changes from baseline in laboratory parameters, vital signs, and ECGs

    Time frame: From ICF signature until 12 months post A-CAR032 infusion

Secondary outcomes

  1. Dose Escalation (Part 1) and Dose Expansion (Part 2):Efficacy

    PSA-related response

    Time frame: From ICF signature until 12 months post A-CAR032 infusion

  2. Dose Escalation (Part 1) and Dose Expansion (Part 2):Efficacy

    Radiological response

    Time frame: From ICF signature until 12 months post A-CAR032 infusion

  3. Dose Escalation (Part 1) and Dose Expansion (Part 2):Efficacy

    rPFS

    Time frame: From ICF signature until 12 months post A-CAR032 infusion

  4. Dose Escalation (Part 1) and Dose Expansion (Part 2):Efficacy

    OS

    Time frame: From ICF signature until 15 years post A-CAR032 infusion

  5. Dose Escalation (Part 1) and Dose Expansion (Part 2):Efficacy

    Time from A-CAR032 infusion to first SSRE

    Time frame: From A-CAR032 infusion until 12 months post A-CAR032 infusion

  6. Dose Escalation (Part 1) and Dose Expansion (Part 2):Pharmacokinetics

    CK profile of A-CAR032

    Time frame: From ICF signature until 15 years post A-CAR032 infusion

07

Study locations

2 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 12 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Jan 15, 2026
StartActual
Jan 13, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2042
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. 2 sites changed recruiting status (2 now not yet recruiting)
Show 2 sites
  • Tongji Hospital, Tongji Medical College of HUST · Wuhan, ChinaRecruiting→Not yet recruiting
  • The Affiliated Hospital of Xuzhou Medical University · Xuzhou, ChinaRecruiting→Not yet recruiting
Show 1 removed
  • Beijing GoBroad Hospital · Beijing, China
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    1 site removed. 2 sites changed recruiting status (2 now not yet recruiting)
    Show 2 sites
    • Tongji Hospital, Tongji Medical College of HUST · Wuhan, ChinaRecruiting→Not yet recruiting
    • The Affiliated Hospital of Xuzhou Medical University · Xuzhou, ChinaRecruiting→Not yet recruiting
    Show 1 removed
    • Beijing GoBroad Hospital · Beijing, China

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07344311
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Jan 13, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2042 (estimated)
Last update
Oct 16, 2026

Study contacts

Andy Zou
Contact
andy.zou@abelzeta.com
+86-21-54069990
Nicole Shen
Contact
yinghua.shen@abelzeta.com
+86-21-54069993

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion